Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation.

Pharmacological reports : PR·2026
Same author

Phototype-related Trichoscopic differences in lichen Planopilaris and frontal Fibrosing alopecia.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Occipital short anagen syndrome: Epidemiological, clinical and trichoscopy features of a case series.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same author

Localized lichen planopilaris without patches: a multicenter retrospective study of 74-patients.

Anais brasileiros de dermatologia·2026
Same author

Is hybrid and gel manicure safe? Current stage of knowledge.

Postepy dermatologii i alergologii·2026

Related Experiment Video

Updated: Jul 2, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Adalimumab in dermatology.

Pawel Traczewski1, Lidia Rudnicka

  • 1Department of Dermatology CSK MSWiA, Warsaw, Poland. paul-tr@wp.pl

British Journal of Clinical Pharmacology
|August 30, 2008
PubMed
Summary
This summary is machine-generated.

Adalimumab, a biologic drug targeting tumor necrosis factor-alpha, effectively treats plaque psoriasis and psoriatic arthritis. It also shows promise for various rare skin conditions, demonstrating a good safety profile.

More Related Videos

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

Related Experiment Videos

Last Updated: Jul 2, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

Area of Science:

  • Immunology
  • Dermatology
  • Rheumatology

Background:

  • Adalimumab is a biologic agent classified as a tumor necrosis factor-alpha inhibitor.
  • Pivotal studies like CHAMPION, REVEAL, and ADEPT have evaluated its efficacy in plaque psoriasis and psoriatic arthritis.

Purpose of the Study:

  • To review the efficacy and safety of Adalimumab in treating plaque psoriasis and psoriatic arthritis.
  • To explore the potential off-label uses of Adalimumab in various dermatological conditions.

Main Methods:

  • Review of pivotal clinical trials (CHAMPION, REVEAL, ADEPT).
  • Analysis of smaller studies and case reports on Adalimumab's efficacy and safety.
  • Assessment of quality of life improvements in patients.

Main Results:

  • Adalimumab demonstrated high efficacy in patients with plaque psoriasis and psoriatic arthritis, including those unresponsive to other treatments.
  • The drug significantly improved patients' quality of life.
  • Available data suggest Adalimumab is safe and well-tolerated, with potential benefits in off-label conditions.

Conclusions:

  • Adalimumab is an effective treatment for plaque psoriasis and psoriatic arthritis.
  • Further research is warranted for its use in other dermatological conditions.
  • Adalimumab presents a favorable safety profile and potential for off-label applications.